

Supplementary Table S1. Additional disease-related data of the 276 systemic lupus erythematosus and 326 rheumatoid arthritis patients.

SLE patients=276		RA patients=326	
SLICC	1 (0-2)	DAS28	3.41 (2.46-4.45)
SLICC ≥ 1	197 (71)	DAS28-CRP	3.26 (2.44-4.11)
Katz Index	2 (1-4)	HAQ	0.750 (0.375-1.125)
Katz Index ≥ 3	104 (38)	SDAI	11.4 (6.0-19.1)
SLEDAI	3 (0-6)	CDAI	30 (9-92)
SLEDAI activity categories, n (%)			
No activity	106 (34)		
Mild	85 (31)		
Moderate	47 (17)		
High or Very High	21 (8)		
ANA profile			
Anti DNA positive, n (%)	165 (60)		
ENA positive, n (%)	66 (24)		
Anti-Ro, n (%)	89 (32)		
Anti-La, n (%)	43 (16)		
Anti-RNP, n (%)	72 (26)		
Anti-Sm, n (%)	34 (12)		
Antiphospholipid autoantibodies			
Lupus anticoagulant, n (%)	67 (24)		
ACA IgM, n (%)	33 (12)		
ACA IgG, n (%)	56 (20)		
Anti beta2 glycoprotein IgM, n (%)	27 (10)		
Anti beta2 glycoprotein IgG, n (%)	39 (14)		
C3, mg/dl	99 $\pm$ 27		
C4, mg/dl	17 $\pm$ 8		
Hypocomplementaemia, n (%)	146 (53)		

Data represent mean $\pm$ SD or median (IQR) when data were not normally distributed.

C3 C4: complement; ANA: antinuclear antibodies; ENA: extractible nuclear antibodies; DMARD: disease-modifying anti-rheumatic drug; ACA: anticardiolipin; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLEDAI categories were defined as: 0, no activity; 1-5 mild; 6-10 moderate; >10 activity; SLICC: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; DAS28: Disease Activation Score using 28 joints; HAQ: Health Assessment Questionnaire; DMARD: disease-modifying anti-rheumatic drug; ESR: erythrocyte sedimentation rate; CDAI: Clinical Disease Activity Index, SDAI: Simple Disease Activity Index.